Publications by authors named "Natsuki Seki"
Background: In recent years, a number of agents possessing novel mechanisms, such as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and PIK3CA inhibitors, have been developed for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor type negative (HER2-) advanced or recurrent breast cancer. As a result, the treatment strategies for advanced or recurrent breast cancer have changed significantly. The combination of CDK 4/6 inhibitors administration and endocrine therapy is now widely used in the treatment of HR+ HER2- recurrent breast cancer with improved outcomes.
View Article and Find Full Text PDFBackground: We modified and administered capecitabine + epirubicin + cyclophosphamide combination therapy (CEX) as neoadjuvant chemotherapy (NAC) for HER-2-negative breast cancer and retrospectively analyzed its effectiveness and tolerability at our center.
Methods: The inclusion criteria were presence of breast cancer negative for HER-2 and positive lymph node metastasis, or negative lymph node metastasis when tumor diameter was 20 mm or greater without distant metastasis. Additional inclusion criteria were a performance status of 0 or 1, an EF >60%, and an age of 75 years or less.
Introduction: The common metastatic sites of renal cell cancer (RCC) are the lung, bone, liver, brain, adrenal glands, and contralateral kidney. Metastasis to the gallbladder is rare, and cystic duct metastasis from RCC has been reported in only one metachronous case. This is the first report of a case of synchronous cystic duct metastasis from RCC.
View Article and Find Full Text PDFArticle Synopsis
- Cutaneous metastasis from internal malignancies, like colorectal cancer, is rare, occurring in only 0.7-9% of cases; this report highlights a unique case involving facial metastasis from sigmoid colon adenocarcinoma.
- A 68-year-old male presented with a tumor on his cheek and had a history of heart issues, kidney failure, and lung disease; biopsies confirmed the cancer's presence on both the face and colon.
- The patient underwent surgery to remove both the colon tumor and facial metastasis and was treated with low-dose chemotherapy; despite stable management, he ultimately died 37 months later due to chronic heart failure.